Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2001 Sep;93(9):335–349.

Modern Pharmacotherapies for Type 2 Diabetes Mellitus

Stanley H Hsia
PMCID: PMC2593969  PMID: 11560289

Abstract

CME Credits

The National Medical Association (NMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education (CME) for physicians.

Readers:

NMA certifies that when CME material is used as directed it meets the criteria for 2 hours of credit in Category I toward the NMA Physician Achievement Award (PAA) or American Medical Association Physician's Recognition Award (PRA).

Each physician should claim only those hours of credit that the physician actually spent in the educational activity. Estimated time for reading the text and taking the CME quiz is approximately 2 hours. The NMA will not maintain any records on individual performance.

Physician readers will receive 2 category I credits upon correctly answering a minimum of 70% of the CME questions at the end of this CME article. Physician readers must send the answers to JNMA/CME, 1012 Tenth St., NW, Washington, DC 20001. Answers to the CME questions accompanying this article must be marked by September 25, 2001.

Authors:

The first or second author of articles published in the Journal of the National Medical Association may claim Category I credit for the NMA PAA or the American Medical Association PRA by including a reprint of the article's first page as part of the PRA or PAA application.

Applications:

PAA application can be obtained by calling NMA's CME office at (202) 347-1895, ext. 241. PRA application can be found by visiting http://www.ama-assn.org/med-sci/pra/prahdr.htm.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akazawa S., Sun F., Ito M., Kawasaki E., Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000 Aug;23(8):1067–1071. doi: 10.2337/diacare.23.8.1067. [DOI] [PubMed] [Google Scholar]
  2. Al-Salman J., Arjomand H., Kemp D. G., Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000 Jan 18;132(2):121–124. doi: 10.7326/0003-4819-132-2-200001180-00006. [DOI] [PubMed] [Google Scholar]
  3. American Diabetes Association Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 2000 Jan;23 (Suppl 1):S43–S46. [PubMed] [Google Scholar]
  4. Balfour J. A., Faulds D. Repaglinide. Drugs Aging. 1998 Aug;13(2):173–180. doi: 10.2165/00002512-199813020-00008. [DOI] [PubMed] [Google Scholar]
  5. Balfour J. A., Plosker G. L. Rosiglitazone. Drugs. 1999 Jun;57(6):921–932. doi: 10.2165/00003495-199957060-00007. [DOI] [PubMed] [Google Scholar]
  6. Baron A., Neumann C. PROTECT interim results: a large multicenter study of patients with type II diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther. 1997 Mar-Apr;19(2):282–295. doi: 10.1016/s0149-2918(97)80116-6. [DOI] [PubMed] [Google Scholar]
  7. Beck-Nielsen H., Hother-Nielsen O., Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med. 1988 Oct;5(7):613–620. doi: 10.1111/j.1464-5491.1988.tb01068.x. [DOI] [PubMed] [Google Scholar]
  8. Bjørnholt J. V., Erikssen G., Aaser E., Sandvik L., Nitter-Hauge S., Jervell J., Erikssen J., Thaulow E. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999 Jan;22(1):45–49. doi: 10.2337/diacare.22.1.45. [DOI] [PubMed] [Google Scholar]
  9. Brooks B., Molyneaux L., Zilkens R., Ross G., Yue D. K. The use of Acarbose in Type 2 diabetic patients in secondary failure: effects on glycaemic control and diet induced thermogenesis. Diabetes Res Clin Pract. 1998 Dec;42(3):175–180. doi: 10.1016/s0168-8227(98)00114-4. [DOI] [PubMed] [Google Scholar]
  10. Buse J. B., Gumbiner B., Mathias N. P., Nelson D. M., Faja B. W., Whitcomb R. W. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care. 1998 Sep;21(9):1455–1461. doi: 10.2337/diacare.21.9.1455. [DOI] [PubMed] [Google Scholar]
  11. Buysschaert M., Bobbioni E., Starkie M., Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Diabet Med. 1999 Feb;16(2):147–153. doi: 10.1046/j.1464-5491.1999.00029.x. [DOI] [PubMed] [Google Scholar]
  12. Carter J. S., Pugh J. A., Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996 Aug 1;125(3):221–232. doi: 10.7326/0003-4819-125-3-199608010-00011. [DOI] [PubMed] [Google Scholar]
  13. Chiasson J. L., Josse R. G., Hunt J. A., Palmason C., Rodger N. W., Ross S. A., Ryan E. A., Tan M. H., Wolever T. M. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994 Dec 15;121(12):928–935. doi: 10.7326/0003-4819-121-12-199412150-00004. [DOI] [PubMed] [Google Scholar]
  14. Chiasson J. L., Josse R. G., Leiter L. A., Mihic M., Nathan D. M., Palmason C., Cohen R. M., Wolever T. M. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996 Nov;19(11):1190–1193. doi: 10.2337/diacare.19.11.1190. [DOI] [PubMed] [Google Scholar]
  15. Coniff R. F., Shapiro J. A., Seaton T. B., Bray G. A. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995 May;98(5):443–451. doi: 10.1016/S0002-9343(99)80343-X. [DOI] [PubMed] [Google Scholar]
  16. Coniff R. F., Shapiro J. A., Seaton T. B., Hoogwerf B. J., Hunt J. A. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care. 1995 Jul;18(7):928–932. doi: 10.2337/diacare.18.7.928. [DOI] [PubMed] [Google Scholar]
  17. Costa B., Piñol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. Diabetes Res Clin Pract. 1997 Oct;38(1):33–40. doi: 10.1016/s0168-8227(97)00083-1. [DOI] [PubMed] [Google Scholar]
  18. Damsbo P., Clauson P., Marbury T. C., Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 1999 May;22(5):789–794. doi: 10.2337/diacare.22.5.789. [DOI] [PubMed] [Google Scholar]
  19. Davalli A. M., Pontiroli A. E., Socci C., Bertuzzi F., Fattor B., Braghi S., Di Carlo V., Pozza G. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J Clin Endocrinol Metab. 1992 Apr;74(4):790–794. doi: 10.1210/jcem.74.4.1548342. [DOI] [PubMed] [Google Scholar]
  20. Davidson M. B., Peters A. L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan;102(1):99–110. doi: 10.1016/s0002-9343(96)00353-1. [DOI] [PubMed] [Google Scholar]
  21. DeFronzo R. A., Goodman A. M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541–549. doi: 10.1056/NEJM199508313330902. [DOI] [PubMed] [Google Scholar]
  22. Del Prato S., Marchetto S., Pipitone A., Zanon M., Vigili de Kreutzenberg S., Tiengo A. Metformin and free fatty acid metabolism. Diabetes Metab Rev. 1995 Sep;11 (Suppl 1):S33–S41. doi: 10.1002/dmr.5610110506. [DOI] [PubMed] [Google Scholar]
  23. Flegal K. M., Carroll M. D., Kuczmarski R. J., Johnson C. L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998 Jan;22(1):39–47. doi: 10.1038/sj.ijo.0800541. [DOI] [PubMed] [Google Scholar]
  24. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000 Apr 5;283(13):1695–1702. doi: 10.1001/jama.283.13.1695. [DOI] [PubMed] [Google Scholar]
  25. Fontbonne A., Charles M. A., Juhan-Vague I., Bard J. M., André P., Isnard F., Cohen J. M., Grandmottet P., Vague P., Safar M. E. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 1996 Sep;19(9):920–926. doi: 10.2337/diacare.19.9.920. [DOI] [PubMed] [Google Scholar]
  26. Franz M. J., Horton E. S., Sr, Bantle J. P., Beebe C. A., Brunzell J. D., Coulston A. M., Henry R. R., Hoogwerf B. J., Stacpoole P. W. Nutrition principles for the management of diabetes and related complications. Diabetes Care. 1994 May;17(5):490–518. doi: 10.2337/diacare.17.5.490. [DOI] [PubMed] [Google Scholar]
  27. Gerich J. E. Oral hypoglycemic agents. N Engl J Med. 1989 Nov 2;321(18):1231–1245. doi: 10.1056/NEJM198911023211805. [DOI] [PubMed] [Google Scholar]
  28. Gitlin N., Julie N. L., Spurr C. L., Lim K. N., Juarbe H. M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998 Jul 1;129(1):36–38. doi: 10.7326/0003-4819-129-1-199807010-00008. [DOI] [PubMed] [Google Scholar]
  29. Goldstein B. J. Rosiglitazone. Int J Clin Pract. 2000 Jun;54(5):333–337. [PubMed] [Google Scholar]
  30. Gottschling-Zeller H., Röhrig K., Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377–383. doi: 10.1007/s001250050057. [DOI] [PubMed] [Google Scholar]
  31. Groop L. C. Sulfonylureas in NIDDM. Diabetes Care. 1992 Jun;15(6):737–754. doi: 10.2337/diacare.15.6.737. [DOI] [PubMed] [Google Scholar]
  32. Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000 Jul 26;284(4):472–477. doi: 10.1001/jama.284.4.472. [DOI] [PubMed] [Google Scholar]
  33. Halimi S., Le Berre M. A., Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000 Sep;50(1):49–56. doi: 10.1016/s0168-8227(00)00163-7. [DOI] [PubMed] [Google Scholar]
  34. Hanefeld M., Bouter K. P., Dickinson S., Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000 Feb;23(2):202–207. doi: 10.2337/diacare.23.2.202. [DOI] [PubMed] [Google Scholar]
  35. Haupt E., Knick B., Koschinsky T., Liebermeister H., Schneider J., Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab. 1991 May;17(1 Pt 2):224–231. [PubMed] [Google Scholar]
  36. Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. Diabet Med. 1997 Jan;14(1):63–72. doi: 10.1002/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  37. Hermann L. S. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care. 1990 Aug;13 (Suppl 3):37–41. doi: 10.2337/diacare.13.3.37. [DOI] [PubMed] [Google Scholar]
  38. Hermann L. S., Scherstén B., Bitzén P. O., Kjellström T., Lindgärde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994 Oct;17(10):1100–1109. doi: 10.2337/diacare.17.10.1100. [DOI] [PubMed] [Google Scholar]
  39. Hermann L. S., Scherstén B., Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1994 Dec;11(10):953–960. doi: 10.1111/j.1464-5491.1994.tb00253.x. [DOI] [PubMed] [Google Scholar]
  40. Hirschberg Y., Karara A. H., Pietri A. O., McLeod J. F. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care. 2000 Mar;23(3):349–353. doi: 10.2337/diacare.23.3.349. [DOI] [PubMed] [Google Scholar]
  41. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care. 1994 Jun;17(6):561–566. doi: 10.2337/diacare.17.6.561. [DOI] [PubMed] [Google Scholar]
  42. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med. 1997 Dec;103(6):483–490. doi: 10.1016/s0002-9343(97)00252-0. [DOI] [PubMed] [Google Scholar]
  43. Holleman F., Hoekstra J. B. Insulin lispro. N Engl J Med. 1997 Jul 17;337(3):176–183. doi: 10.1056/NEJM199707173370307. [DOI] [PubMed] [Google Scholar]
  44. Horton E. S., Whitehouse F., Ghazzi M. N., Venable T. C., Whitcomb R. W. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998 Sep;21(9):1462–1469. doi: 10.2337/diacare.21.9.1462. [DOI] [PubMed] [Google Scholar]
  45. Inzucchi S. E., Maggs D. G., Spollett G. R., Page S. L., Rife F. S., Walton V., Shulman G. I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998 Mar 26;338(13):867–872. doi: 10.1056/NEJM199803263381303. [DOI] [PubMed] [Google Scholar]
  46. Isley W. L., Oki J. C. Rosiglitazone and liver failure. Ann Intern Med. 2000 Sep 5;133(5):393–394. doi: 10.7326/0003-4819-133-5-200009050-00022. [DOI] [PubMed] [Google Scholar]
  47. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med. 1996 Apr;13(4):365–370. doi: 10.1002/(SICI)1096-9136(199604)13:4<365::AID-DIA19>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  48. Iwase M., Yamaguchi M., Yoshinari M., Okamura C., Hirahashi T., Tsuji H., Fujishima M. A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care. 1999 Aug;22(8):1382–1384. doi: 10.2337/diacare.22.8.1382. [DOI] [PubMed] [Google Scholar]
  49. Jeppesen J., Zhou M. Y., Chen Y. D., Reaven G. M. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994 Oct;17(10):1093–1099. doi: 10.2337/diacare.17.10.1093. [DOI] [PubMed] [Google Scholar]
  50. Jeppesen J., Zhou M. Y., Chen Y. D., Reaven G. M. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994 Oct;17(10):1093–1099. doi: 10.2337/diacare.17.10.1093. [DOI] [PubMed] [Google Scholar]
  51. Johnston P. S., Coniff R. F., Hoogwerf B. J., Santiago J. V., Pi-Sunyer F. X., Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care. 1994 Jan;17(1):20–29. doi: 10.2337/diacare.17.1.20. [DOI] [PubMed] [Google Scholar]
  52. Johnston P. S., Lebovitz H. E., Coniff R. F., Simonson D. C., Raskin P., Munera C. L. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998 May;83(5):1515–1522. doi: 10.1210/jcem.83.5.4824. [DOI] [PubMed] [Google Scholar]
  53. King H., Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care. 1993 Jan;16(1):157–177. doi: 10.2337/diacare.16.1.157. [DOI] [PubMed] [Google Scholar]
  54. Lam K. S., Tiu S. C., Tsang M. W., Ip T. P., Tam S. C. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care. 1998 Jul;21(7):1154–1158. doi: 10.2337/diacare.21.7.1154. [DOI] [PubMed] [Google Scholar]
  55. Laube B. L., Georgopoulos A., Adams G. K., 3rd Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA. 1993 Apr 28;269(16):2106–2109. [PubMed] [Google Scholar]
  56. Lebovitz H. E. alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am. 1997 Sep;26(3):539–551. doi: 10.1016/s0889-8529(05)70266-8. [DOI] [PubMed] [Google Scholar]
  57. Lee A., Morley J. E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53. doi: 10.1002/j.1550-8528.1998.tb00314.x. [DOI] [PubMed] [Google Scholar]
  58. Lefèbvre P. J., Scheen A. J. Glucose metabolism and the postprandial state. Eur J Clin Invest. 1999 Jun;29 (Suppl 2):1–6. doi: 10.1046/j.1365-2362.1999.00003.x. [DOI] [PubMed] [Google Scholar]
  59. Malaisse W. J., Lebrun P. Mechanisms of sulfonylurea-induced insulin release. Diabetes Care. 1990 Aug;13 (Suppl 3):9–17. doi: 10.2337/diacare.13.3.9. [DOI] [PubMed] [Google Scholar]
  60. Marbury T., Huang W. C., Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999 Mar;43(3):155–166. doi: 10.1016/s0168-8227(99)00002-9. [DOI] [PubMed] [Google Scholar]
  61. Marena S., Tagliaferro V., Montegrosso G., Pagano A., Scaglione L., Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab. 1994 Jan-Feb;20(1):15–19. [PubMed] [Google Scholar]
  62. Meigs J. B., Nathan D. M., Wilson P. W., Cupples L. A., Singer D. E. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med. 1998 Apr 1;128(7):524–533. doi: 10.7326/0003-4819-128-7-199804010-00002. [DOI] [PubMed] [Google Scholar]
  63. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., Zanolin E., Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 Jan;85(1):139–146. doi: 10.1210/jcem.85.1.6293. [DOI] [PubMed] [Google Scholar]
  64. Mori Y., Murakawa Y., Okada K., Horikoshi H., Yokoyama J., Tajima N., Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999 Jun;22(6):908–912. doi: 10.2337/diacare.22.6.908. [DOI] [PubMed] [Google Scholar]
  65. Moses R., Slobodniuk R., Boyages S., Colagiuri S., Kidson W., Carter J., Donnelly T., Moffitt P., Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999 Jan;22(1):119–124. doi: 10.2337/diacare.22.1.119. [DOI] [PubMed] [Google Scholar]
  66. Neuschwander-Tetri B. A., Isley W. L., Oki J. C., Ramrakhiani S., Quiason S. G., Phillips N. J., Brunt E. M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998 Jul 1;129(1):38–41. doi: 10.7326/0003-4819-129-1-199807010-00009. [DOI] [PubMed] [Google Scholar]
  67. Ovalle F., Bell D. S. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 1998 May-Jun;4(3):146–147. doi: 10.4158/EP.4.3.146. [DOI] [PubMed] [Google Scholar]
  68. Parulkar A. A., Pendergrass M. L., Granda-Ayala R., Lee T. R., Fonseca V. A. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001 Jan 2;134(1):61–71. doi: 10.7326/0003-4819-134-1-200101020-00014. [DOI] [PubMed] [Google Scholar]
  69. Peters A. L., Davidson M. B. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab. 1996 Jul;81(7):2423–2427. doi: 10.1210/jcem.81.7.8675555. [DOI] [PubMed] [Google Scholar]
  70. Pinhas-Hamiel O., Dolan L. M., Daniels S. R., Standiford D., Khoury P. R., Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996 May;128(5 Pt 1):608–615. doi: 10.1016/s0022-3476(96)80124-7. [DOI] [PubMed] [Google Scholar]
  71. Plosker G. L., Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 1999 Mar;57(3):409–438. doi: 10.2165/00003495-199957030-00014. [DOI] [PubMed] [Google Scholar]
  72. Polonsky K. S., Sturis J., Bell G. I. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996 Mar 21;334(12):777–783. doi: 10.1056/NEJM199603213341207. [DOI] [PubMed] [Google Scholar]
  73. Raskin P., Jovanovic L., Berger S., Schwartz S., Woo V., Ratner R. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care. 2000 Jul;23(7):979–983. doi: 10.2337/diacare.23.7.979. [DOI] [PubMed] [Google Scholar]
  74. Rosenstock J., Brown A., Fischer J., Jain A., Littlejohn T., Nadeau D., Sussman A., Taylor T., Krol A., Magner J. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998 Dec;21(12):2050–2055. doi: 10.2337/diacare.21.12.2050. [DOI] [PubMed] [Google Scholar]
  75. Rosskamp R. H., Park G. Long-acting insulin analogs. Diabetes Care. 1999 Mar;22 (Suppl 2):B109–B113. [PubMed] [Google Scholar]
  76. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G., Ming U. T., Baird S. M., Thomazy V. A., Evans R. M. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998 Sep;4(9):1058–1061. doi: 10.1038/2042. [DOI] [PubMed] [Google Scholar]
  77. Schwartz S., Raskin P., Fonseca V., Graveline J. F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998 Mar 26;338(13):861–866. doi: 10.1056/NEJM199803263381302. [DOI] [PubMed] [Google Scholar]
  78. Segal P., Feig P. U., Schernthaner G., Ratzmann K. P., Rybka J., Petzinna D., Berlin C. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997 May;20(5):687–691. doi: 10.2337/diacare.20.5.687. [DOI] [PubMed] [Google Scholar]
  79. Shibuya A., Watanabe M., Fujita Y., Saigenji K., Kuwao S., Takahashi H., Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998 Dec;21(12):2140–2143. doi: 10.2337/diacare.21.12.2140. [DOI] [PubMed] [Google Scholar]
  80. Spiegelman B. M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998 Apr;47(4):507–514. doi: 10.2337/diabetes.47.4.507. [DOI] [PubMed] [Google Scholar]
  81. Stout R. W. Insulin and atheroma. 20-yr perspective. Diabetes Care. 1990 Jun;13(6):631–654. doi: 10.2337/diacare.13.6.631. [DOI] [PubMed] [Google Scholar]
  82. Vella A., de Groen P. C., Dinneen S. F. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med. 1998 Dec 15;129(12):1080–1080. doi: 10.7326/0003-4819-129-12-199812150-00032. [DOI] [PubMed] [Google Scholar]
  83. Walker A. B., Chattington P. D., Buckingham R. E., Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999 Jul;48(7):1448–1453. doi: 10.2337/diabetes.48.7.1448. [DOI] [PubMed] [Google Scholar]
  84. Walter Y. H., Spratt D. I., Garreffa S., McLeod J. F. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. Eur J Clin Pharmacol. 2000 May;56(2):129–133. doi: 10.1007/s002280050730. [DOI] [PubMed] [Google Scholar]
  85. Watkins P. B., Whitcomb R. W. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998 Mar 26;338(13):916–917. doi: 10.1056/NEJM199803263381314. [DOI] [PubMed] [Google Scholar]
  86. Yki-Järvinen H., Dressler A., Ziemen M., HOE 901/300s Study Group Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000 Aug;23(8):1130–1136. doi: 10.2337/diacare.23.8.1130. [DOI] [PubMed] [Google Scholar]
  87. Yki-Järvinen H., Kauppila M., Kujansuu E., Lahti J., Marjanen T., Niskanen L., Rajala S., Ryysy L., Salo S., Seppälä P. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992 Nov 12;327(20):1426–1433. doi: 10.1056/NEJM199211123272005. [DOI] [PubMed] [Google Scholar]
  88. Yki-Järvinen H., Ryysy L., Nikkilä K., Tulokas T., Vanamo R., Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999 Mar 2;130(5):389–396. doi: 10.7326/0003-4819-130-5-199903020-00002. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES